GB2255718A - Pharmaceutical composition for treating equine viral infections - Google Patents
Pharmaceutical composition for treating equine viral infections Download PDFInfo
- Publication number
- GB2255718A GB2255718A GB9110413A GB9110413A GB2255718A GB 2255718 A GB2255718 A GB 2255718A GB 9110413 A GB9110413 A GB 9110413A GB 9110413 A GB9110413 A GB 9110413A GB 2255718 A GB2255718 A GB 2255718A
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- mixture
- viral infections
- caffeine
- potassium iodide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000036142 Viral infection Diseases 0.000 title claims abstract description 18
- 230000009385 viral infection Effects 0.000 title claims abstract description 18
- 241000283073 Equus caballus Species 0.000 title claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 29
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims abstract description 24
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 18
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims abstract description 12
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960001948 caffeine Drugs 0.000 claims abstract description 9
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000019270 ammonium chloride Nutrition 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims 1
- 241000283086 Equidae Species 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- VQLYBLABXAHUDN-UHFFFAOYSA-N bis(4-fluorophenyl)-methyl-(1,2,4-triazol-1-ylmethyl)silane;methyl n-(1h-benzimidazol-2-yl)carbamate Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1.C=1C=C(F)C=CC=1[Si](C=1C=CC(F)=CC=1)(C)CN1C=NC=N1 VQLYBLABXAHUDN-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Pharmaceutical composition for treating equine viral infections which includes potassium iodide, ammonium chloride and caffeine is disclosed. The composition may also contain aqueous chloroform.
Description
This invention relates to a treatment and/or a method of treating and has been designed particularly though solely for use in the treatment of equine viral infections.
Horses are particularly prone to viral infections such as Herpes Virus Number 1. Those viral infections are often present in association with bacterial infections. The symptoms include coughing and difficulty in breathing (probably a result of bronchitis), mucous formation, lethargy, wight loss, occasionally nose bleeding and pimples in the nostrils as well as weeping eyes.
The overall outcome of these infection. is poor racing performance and overall appearance as well as lack of coat lustre.
In order to treat these infections, several veterinary preparations have boen developed. However, most of these treatments only combat bacterial infections and therefore their usefulness is limited as they have no effect on viral infections. Bromoprimidine and Vendripulmin are conunonly used to treat equine viral infections but these compounds appear to only exert their effect on bacterial infections.
It is therefor an object of the present invention to provide a treatment and/or a method of treating which will go at least someway to overcoming the forging diserata or which will at least provide the public with a useful
Accordingly in one aspect the invention consists in a treatment comprising a iixture of potassium iodide, a-oniui chloride and caffeine.
In a further aspect the invention consists in a method of treating viral infections by adinistering between substantially 30ml and substantially 120ml of a mixture according to the preceding paragraph on a daily basis.
To those skilled in the art to which the invention relates, many changes in construction and widely differing embodiments and applications of the invention will suggest themselves without departing from the scope of the invention as defined in the appended c la . The disclosure and the descriptions herein are purely illustrative and are not intended to be in any sense limiting.
One preferred form of the invention will now be described.
In the preferred form of the invention a treatment and a method of treating in particular equine viral infections are provided. However, the treatment can be used to treat other animals such as cats, dogs and calves. Further, the treatment was found to have further applications such as blooming a healthy horse and may exert an inhibitory effect on bacterial infections which are commonly associated with viral infections.
A mixture is provided which includes potassium iodide, ammoniun chloride and caffeine. The caffeine is desirably caffein alk. Preferably, the mixture also includes aqueous chloroform and the mixture is provided in a suitable carrier material of knows types.
In an example of the mixture described the potassium iodide is desirably present in an amount between substantially 100mg and substantially 400mg , more preferably between substantially 180mg and substantially 220mg, and desirably substantially 2nnm.
The ammonium chloride is again preferably present in amount between substantially 100mg and substantially 400mg, substantially 180mg to substantially 220mg and desirably preferably substantially 200mg.
The caffeine alk is desirably present in amounts between substantially 100mg and substantially OOmg, preferably substantially lS0mg to substantially 220mg and desirably substantially 200mg.
Aqueous chloroform is desirably provided as the chloroform acts as a preservative. The aqueous chloroform may for example be present in amounts in the described quantity of between substantially 5ml and substantially 20ml preferably substantially 6m1 to substantially 12m1 and more preferably substantially 10X1.
However, any one skilled in the art will appreciate that any other suitable preservative may be used and further compounds can be included in the composition if desired.
The mixture is for example made up to about 500ml with any suitable carrier.
The mixture is used to treat equine viral infections by administering to a horse between substantially 30ml and substantially 120ml of the mixture on a daily basis.
However, if the treatment is to be administrered to an animal other than a horse the amount of mixture administered can be varied according to the body weight of the animal. The mixture is preferably administered orally but alternative administration moons are envisgaged by the applicant. The preferred dose is about 60ml per day and the upper and lower limits are set because too groat a quantity may have a toxicity which is too great for the animal whereas, of course, too low a quantity will reduce the efficacy of the mixture.
It is found that the mixture tends to act as a bronchodilator and also tend to dry up the mucus whilst acting as an expectorant.
The inventor has administered the treatment of over 200 horses suffering from what was diagnosed to be viral infections and experienced a 90t success rate in obviating the symptoms. The various symptoms displayed by the horses tested were aoughlng, wheezing, mucous formation, lethargy and ocassional nose bleeding and spot or pimple formation in the nose.These symptoms obviously effected the horse's racing performance and overall appearance After treatment with the mixture disclosed herein it was found that, in aost instances, the symptoms were no longer displayed by the horses within a period of about 14 days and many of the horses treated won races after the treatment. When using the treatment it was found that in order to avoid recurrences of the symptoms the horse should not be "tregeed too soon after treatment.
The applicant he prepared several working sheets which clearly detail the effectiveness of the mixture for combatting the symptoms thought to be assocciated with viral infections. Many of these sheets have been signed by veterinarians witnessing the effectiveness of the composition. Several horses had been treated for up to two years with known drug. such as Bromoprimidine and
Ventripulmin showing little improvement. However, treatment with the composition of the instant invention obviated the symptoms displayed by these horses.
The inventor has also administered the composition to healthy horses and it was found that the sheen of the horns coat was proved. This was found to occur in unhealthy animals as well. further, the treatment appeared to cure staggers a The inventor has also administered the colposition to several cats and dogs and calves which appeared to be suffering from viral infections and an overall clearing of the symptoms was observed.
Not wishing to be bound by any theory it is hypothesised that tho method by which the mixture effects its result is possibly due to the fact that the salts contained in the mixture are either salts of a strong base and a weak acid or a weak base and a strong acid. The applicant also believes that in solution complexes are formed which are only weakly soluble thereby giving a slow release of the materials.
It is believed that it will be found that administration of the above mixtures to horses in substantially the amount shown will give substantial relief to those horses suffering from equine viral infections.
Thus it can be seen that a treatment and method of troating is provided which will give relief, in particular, to horses havlng equine viral infections and it is found that the mixture gives greater relief than other presently known treatments such as antibiotics.
Claims (1)
- CLAIM:1. A treatment comprising a mixture of potassium iodide, ammonium chloride and caffeine.2. A treatment as claimed in Claim 1 wherein raid composition is suitable for the treatment o equine viral infections.3. A treatment as claimed in Claim 1 or Claim 2 wherein said mixture further includes aqueous chloroform.4. A treatment as claimed in any one of the preceding claims wherein said ingredients are present in a ratio represented by potassium iodide between substantially 100mg and substantially 400mg, ammonium chloride between substantially lOOmg and substantially 4OOmg, and caffeine between substantially lOOmg and substantially 4OOmg, said mixture being made up to substantially 500ml.5. A treatment as claimed in claim 4 wherein said potassium iodide is between substantially 180mg and substantially 220mg, said ammonium chloride between substantially 180mg and 220mg and said caffeine between substantially leOmg and substantially 220mg, said mixture being made up to substantially fOOml.6. A treatment as claimed in Claim 5 wherein said potassium iodide is substantially 200mg, said ammonium chloride substantially 200mg, said caffeine substantially 200mg, being made up to substantially 500ml.7. A treatment as claimed in any one or more of the preceding claims wherein said chloroform is provided in an amount between substantially Smi and substantially 20m1.ss. A treatment as claimed in claim 7 wherein said chloroform is provided in an amount between substantially 8ml and substantially 12ml, 9. A treatment as claimed in claim 8 wherein said chloroform is present in an amount of substantially 10ml.10. A method of treating equine viral infections by administering between substantially 30ml and substantially 120ml of a mixture according to any one of the preceding paragraphs on a daily basis.X A method as claimed in Claim 10 wherein said daily dosage comprises substantially 60t1 per day.12. A treatment substantially as hereinbefore described with reference to any one or more of the examples.13. A method of treating substantially as hereinbefore described with reference to any one or more of the examples.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ23132289A NZ231322A (en) | 1989-11-08 | 1989-11-08 | Treatment of viral and/or bacterial infections |
| NZ23397390A NZ233973A (en) | 1989-11-08 | 1990-06-07 | Treatment of viral and/or bacterial infections |
| CA002042534A CA2042534C (en) | 1989-11-08 | 1991-05-14 | Treatment and/or a method of treating |
| JP3205011A JP2731051B2 (en) | 1989-11-08 | 1991-05-15 | Pharmaceutical composition for equine virus infection and method of treating the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB9110413D0 GB9110413D0 (en) | 1991-07-03 |
| GB2255718A true GB2255718A (en) | 1992-11-18 |
| GB2255718B GB2255718B (en) | 1995-05-10 |
Family
ID=27426852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9110413A Expired - Fee Related GB2255718B (en) | 1989-11-08 | 1991-05-14 | Pharmaceutical composition for treating bacterial and / or viral infection |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2731051B2 (en) |
| AU (1) | AU642173B2 (en) |
| CA (1) | CA2042534C (en) |
| GB (1) | GB2255718B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999011276A1 (en) * | 1997-09-02 | 1999-03-11 | Oswald Edmonds Hooper | Medicament including potassium iodide and ammonium chloride |
| WO2009067067A1 (en) * | 2007-11-23 | 2009-05-28 | Pharmalundensis Ab | Method and means for obtaining bronchorelaxation |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996032952A1 (en) * | 1995-04-21 | 1996-10-24 | Oswald Edmonds Hooper | Caffeine composition as medicament and use thereof |
| US8840934B2 (en) * | 2009-01-02 | 2014-09-23 | Rainbow Pharmaceutical Sa | Uses of ammonium chloride |
-
1990
- 1990-11-07 AU AU65875/90A patent/AU642173B2/en not_active Ceased
-
1991
- 1991-05-14 GB GB9110413A patent/GB2255718B/en not_active Expired - Fee Related
- 1991-05-14 CA CA002042534A patent/CA2042534C/en not_active Expired - Fee Related
- 1991-05-15 JP JP3205011A patent/JP2731051B2/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999011276A1 (en) * | 1997-09-02 | 1999-03-11 | Oswald Edmonds Hooper | Medicament including potassium iodide and ammonium chloride |
| AU751364B2 (en) * | 1997-09-02 | 2002-08-15 | Oswald Edmonds Hooper | Medicament including potassium iodide and ammonium chloride |
| WO2009067067A1 (en) * | 2007-11-23 | 2009-05-28 | Pharmalundensis Ab | Method and means for obtaining bronchorelaxation |
| EA017359B1 (en) * | 2007-11-23 | 2012-11-30 | Фармалунденсис Аб | Method and composition for obtaining bronchorelaxation |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH05112457A (en) | 1993-05-07 |
| GB9110413D0 (en) | 1991-07-03 |
| CA2042534C (en) | 1996-11-12 |
| CA2042534A1 (en) | 1992-11-15 |
| GB2255718B (en) | 1995-05-10 |
| AU642173B2 (en) | 1993-10-14 |
| AU6587590A (en) | 1991-05-16 |
| JP2731051B2 (en) | 1998-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU760870B2 (en) | Method and composition for the treatment of epidermal irritations and infections | |
| HK1054197B (en) | Anti-infective active substance combinations and the use thereof for the topical treatment of fungus diseases of toe and finger nails | |
| JPH0586379B2 (en) | ||
| JP2002521428A (en) | Use of L-carnitine and its alkanoyl derivative for the manufacture of a medicament having anticancer activity | |
| JP2002526407A (en) | Fulvic acid and its use in treating various conditions | |
| RU2000132310A (en) | APPLICATION OF MAGNESIUM-BASED PRODUCTS FOR TREATMENT OR PREVENTION OF TUMOR AND AUTOIMMUNE DISEASES | |
| Deleforge et al. | A field evaluation of the efficacy of tolfenamic acid and oxytetracycline in the treatment of bovine respiratory disease | |
| EP1171124B2 (en) | Anthelmintic compositions | |
| RU97104483A (en) | SUITABLE ACID SALT 4- [2-AMINO-6- (CYCLOPROPYLAMINO) -9H-PURIN-9-IL] -2- CYCLOPENTEN-1-METHANOL AS ANTI-VIRUS AGENT | |
| DE69232911T2 (en) | Use of a polyhydroxybenzamide or its derivative in the manufacture of a medicament for the treatment of viral infections | |
| GB2255718A (en) | Pharmaceutical composition for treating equine viral infections | |
| DE3601923A1 (en) | NASAL APPLICABLE MEDICINE, METHOD FOR THE PRODUCTION AND USE THEREOF | |
| US5275828A (en) | Treatment and/or a method of treating equine viral and bacterial infections | |
| CN105726523B (en) | It is a kind of to be used to treat pharmaceutical composition of animal acariasis and its preparation method and application | |
| JPS59205321A (en) | Anthelmintic synergistical novel composition | |
| RU2108108C1 (en) | Preparation possessing adaptogenic effect (versions) | |
| RU2204384C1 (en) | Composition for treating and preventing vertebrates against parasites | |
| CA1174169A (en) | Orally active tolciclate and tolnaftate | |
| Aitken et al. | Plasma levels following administration of sodium meclofenamate by various routes | |
| US4117141A (en) | Method of inhibiting flea-bite allergy | |
| RU2287332C2 (en) | Preparation for preventing and treating helmintiases in animals | |
| RU2204383C1 (en) | Method for treating and preventing diseases induced by ticks and gadflies in vertebrates | |
| RU2799015C1 (en) | Method of local treatment of hoof diseases in cattle based on a combination of active ingredients | |
| RU2123332C1 (en) | Anthelminthic agent | |
| JPH061721A (en) | Pain treating agent and pain mitigating activity potentiator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20060514 |